Dashboard
Manage Tickers

IPSEFIPSEN


$ 14.90 (12.67 %)    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 454.82 $ -0.84 (-0.19 %)
DIA $ 398.57 $ 6.05 (1.59 %)
SPY $ 530.36 $ 4.76 (0.91 %)
TLT $ 91.26 $ 0.61 (0.68 %)
GLD $ 225.37 $ -1.27 (-0.59 %)
$ 132.5
-- x --
-- x --
-- - --
$ 108.75 - $ 132.50
2,236
na
nm
$ -0.63
nm
TBD
na
na (nm)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Ipsen And Sutro Biopharma Enter Exclusive ...
04/02/2024 05:49:31

Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completi...

Core News & Articles
Merrimack Secures $225M Milestone Payment ...
03/27/2024 20:34:00

The company has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of approval from the ...

third-time-lucky-exelixis-cabozantinib-combo-therapy-aces-pivotal-study-in-prostate-cancer-patients
Third Time Lucky: Exelixis' Cabozantinib C...
08/21/2023 18:57:49

Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs

what-now-after-fda-adcomm-rebuke-for-intercept-pharmaceutical-analyst-says-approval-of-intercepts-oca-in-nash-may-never-occur
What Now After FDA AdComm Rebuke for Inter...
05/22/2023 20:20:42

On Friday, FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercep...

france-based-ipsen-acquires-albireo-pharma-enriching-its-rare-disease-portfolio-pipeline
France-Based Ipsen Acquires Albireo Pharma...
01/09/2023 11:24:09

why-merrimack-shares-are-surging-over-200-today
Why Merrimack Shares Are Surging Over 200%...
11/09/2022 14:04:12

merrimack-pharma-ipsens-cancer-drug-fails-in-overall-survival-measure
Merrimack Pharma-Ipsen's Cancer Drug Fails...
08/03/2022 15:49:40

ipsen-scoops-up-blood-cancer-focused-epizyme---read-why
Ipsen Scoops Up Blood Cancer-Focused Epizy...
06/27/2022 10:45:30

Ipsen SA (OTC: IPSEY) has 

ipsen---exelixis-cabometyx-scores-european-approval-as-second-line-treatment-for-thyroid-cancer
Ipsen - Exelixis' Cabometyx Scores Europea...
05/03/2022 09:54:59

emas-scientific-committee-backs-expanded-use-of-exelixis-ipsens-cabometyx-in-thyroid-cancer
EMA's Scientific Committee Backs Expanded ...
03/25/2022 17:41:53

Exelixis Inc (NASDAQ: EXEL) and its partner Ipsen SA (OTC: IPSEY) have 

ipsens-sohonos-scores-canadian-approval-for-rare-connective-tissue-disease
Ipsen's Sohonos Scores Canadian Approval F...
01/24/2022 10:54:51

genfit-shares-rally-after-ipsen-buys-rights-to-its-late-stage-kidney-disease-treatment-hopeful
Genfit Shares Rally After Ipsen Buys Right...
12/17/2021 11:25:03

Ipsen SA (OTC: IPSEY) has 

ipsen-stock-declines-after-pulling-rare-disease-application
Ipsen Stock Declines After Pulling Rare Di...
08/13/2021 14:48:49

exicure-stock-surges-on-over-1b-option-licensing-pact-with-ipsen-for-rare-neurodegenerative-disorders
Exicure Stock Surges On Over $1B Option Li...
08/02/2021 11:24:48

exelixis-shares-drop-on-mixed-results-for-cabometyx-combo-in-early-liver-cancer
Exelixis Shares Drop On Mixed Results For ...
06/28/2021 12:40:04

Core News & Articles
European Medicines Agency's CHMP Backs App...
02/26/2021 17:55:43

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION